Cargando…

MET gene alterations predict poor survival following chemotherapy in patients with advanced cancer

Background: To aid in oncology drug development, we investigated MET proto-oncogene receptor tyrosine kinase gene aberrations in 2,239 oncology patients who underwent next-generation sequencing (NGS) in clinical practice. Materials and methods: From November 2019 to January 2021, 2,239 patientswith...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ko, Jihoon, Jung, Jaeyun, Kim, Seung Tae, Hong, Jung Yong, Park, Sehhoon, Park, Joon Oh, Park, Young Suk, Lim, Ho Yeong, Ahn, Soomin, Kim, Kyoung-Mee, Kang, Won Ki, Lee, Jeeyun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pathology and Oncology Archive
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9722768/ https://www.ncbi.nlm.nih.gov/pubmed/36483096 http://dx.doi.org/10.3389/pore.2022.1610697

Ejemplares similares

Impact of programmed death‐ligand 1 (PD‐L1) positivity on clinical and molecular features of patients with metastatic gastric cancer
por: Shin, Minkyue, et al.
Publicado: (2023)

Prognostic Value of Highly Expressed Type VII Collagen (COL7A1) in Patients With Gastric Cancer
por: Oh, Sung Eun, et al.
Publicado: (2021)

The Clinical Impact of c-MET Over-Expression in Advanced Biliary Tract Cancer (BTC)
por: Heo, Mi Hwa, et al.
Publicado: (2017)

The prevalence of homologous recombination deficiency (HRD) in various solid tumors and the role of HRD as a single biomarker to immune checkpoint inhibitors
por: Kim, Hana, et al.
Publicado: (2021)

TP53 mutations predict poor response to immunotherapy in patients with metastatic solid tumors
por: Kim, Ji‐Yeon, et al.
Publicado: (2023)

Immunohistochemical Expressions of Senescence-Associated Secretory Phenotype and Its Association With Immune Microenvironments and Clinicopathological Factors in Invasive Breast Cancer
por: Park, Min Hui, et al.
Publicado: (2021)

Tumor budding as a predictor of disease-free survival in patients with cholangiocarcinoma
por: Kim, Kyung Bin, et al.
Publicado: (2023)

Gastrointestinal malignancies harbor actionable MET exon 14 deletions
por: Lee, Jeeyun, et al.
Publicado: (2015)

The Impact of PD-L1 Expression in Patients with Metastatic GEP-NETs
por: Kim, Seung Tae, et al.
Publicado: (2016)

Patient-derived exosomes facilitate therapeutic targeting of oncogenic MET in advanced gastric cancer
por: Hyung, Sujin, et al.
Publicado: (2023)

Incidence of FGFR2 Amplification and FGFR2 Fusion in Patients with Metastatic Cancer Using Clinical Sequencing
por: Hyung, Sujin, et al.
Publicado: (2022)

Overexpression of Dehydrogenase/Reductase 9 Predicts Poor Response to Concurrent Chemoradiotherapy and Poor Prognosis in Rectal Cancer Patients
por: Chen, Tzu-Ju, et al.
Publicado: (2022)

Case Report: Papillary Lesions at the Mouth Floor May Mimic Sialadenoma Papilliferum
por: Han, Dawool, et al.
Publicado: (2022)

Screening and Validation of Independent Predictors of Poor Survival in Pancreatic Cancer
por: Liu, Shui, et al.
Publicado: (2021)

Claudin 18.2 expression in various tumor types and its role as a potential target in advanced gastric cancer
por: Hong, Jung Yong, et al.
Publicado: (2020)

Highly expressed FAM189B predicts poor prognosis in hepatocellular carcinoma
por: Ma, Wanshan, et al.
Publicado: (2022)

Clinicopathological Implications of ASAP1 Expression in Hepatocellular Carcinoma
por: Bang, Seongsik, et al.
Publicado: (2022)

High tumor mutational burden predicts favorable response to anti-PD-(L)1 therapy in patients with solid tumor: a real-world pan-tumor analysis
por: Jung, Jaeyun, et al.
Publicado: (2023)

Influence of the microbiota on the effectiveness and toxicity of oncological therapies, with a focus on chemotherapy
por: Cazzaniga, Massimiliano, et al.
Publicado: (2023)

Low Expression of Stanniocalcin 1 (STC-1) Protein Is Associated With Poor Clinicopathologic Features of Endometrial Cancer
por: Khatun, Masuma, et al.
Publicado: (2021)

Cancer-Associated Stromal Fibroblast-Derived Transcriptomes Predict Poor Clinical Outcomes and Immunosuppression in Colon Cancer
por: Wang, Jie, et al.
Publicado: (2022)

High expression of TMEM200A is associated with a poor prognosis and immune infiltration in gastric cancer
por: Deng, Hongyang, et al.
Publicado: (2023)

Cytokine-induced killer cell treatment is superior to chemotherapy alone in esophageal cancer
por: Sun, Jiayang, et al.
Publicado: (2023)

Clinical sequencing to assess tumor mutational burden as a useful biomarker to immunotherapy in various solid tumors
por: Kim, Hana, et al.
Publicado: (2021)

Pelvic lymph node decidua mimicking metastatic cervical cancer in pregnancy
por: Pfaendler, Krista S, et al.
Publicado: (2022)

Intracystic endometrioid borderline tumor
por: El Hajj, Houssein, et al.
Publicado: (2023)

Predictive role of neostromal CD10 expression in breast cancer patients treated with neoadjuvant chemotherapy
por: Olah, Orsolya, et al.
Publicado: (2023)

Identification of an Oxidative Stress-Related LncRNA Signature for Predicting Prognosis and Chemotherapy in Patients With Hepatocellular Carcinoma
por: Zhong, Zixuan, et al.
Publicado: (2022)

In Gastric Cancer Patients Receiving Neoadjuvant Chemotherapy Systemic Inflammation Response Index is a Useful Prognostic Indicator
por: Chen, Li, et al.
Publicado: (2021)

Thrombospondin 2 is a Functional Predictive and Prognostic Biomarker for Triple-Negative Breast Cancer Patients With Neoadjuvant Chemotherapy
por: Lin, Yuxiang, et al.
Publicado: (2022)

Comprehensive molecular analysis to predict the efficacy of chemotherapy containing bevacizumab in patients with metastatic colorectal cancer
por: LIM, SUNG HEE, et al.
Publicado: (2023)

Pretreatment C-Reactive Protein/Albumin Ratio is Associated With Poor Survival in Patients With 2018 FIGO Stage IB-IIA HPV-Positive Cervical Cancer
por: Jiang, Yinan, et al.
Publicado: (2021)

Pretreatment Systemic Immune-Inflammation Index Can Predict Response to Neoadjuvant Chemotherapy in Cervical Cancer at Stages IB2-IIB
por: Liu, Pingping, et al.
Publicado: (2022)

Mechanisms of Acquired Resistance to Savolitinib, a Selective MET Inhibitor in MET-Amplified Gastric Cancer
por: Frigault, Melanie M., et al.
Publicado: (2020)

The Clinicopathological Significance of YAP/TAZ Expression in Hepatocellular Carcinoma with Relation to Hypoxia and Stemness
por: Park, Hyunjin, et al.
Publicado: (2021)

The impact of microsatellite instability status and sidedness of the primary tumor on the effect of bevacizumab-containing chemotherapy in patients with metastatic colorectal cancer
por: Kim, Seung Tae, et al.
Publicado: (2018)

A Single Arm, Phase II Study of Simvastatin Plus XELOX and Bevacizumab as First-Line Chemotherapy in Metastatic Colorectal Cancer Patients
por: Kim, Youjin, et al.
Publicado: (2019)

The Prognostic Role of PORT and EGFR Mutation Status in Completely Resected Stage IIIA/N2 Non-Small Cell Lung Cancer Patients with Postoperative Chemotherapy
por: Yang, Hui, et al.
Publicado: (2021)

Correlating programmed death ligand 1 (PD-L1) expression, mismatch repair deficiency, and outcomes across tumor types: implications for immunotherapy
por: Kim, Seung Tae, et al.
Publicado: (2017)

The Impact of Microsatellite Instability Status and Sidedness of the Primary Tumor on the Effect of Cetuximab-Containing Chemotherapy in Patients with Metastatic Colorectal Cancer
por: Kim, Seung Tae, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_sn8jgum2dofu44vu1rkjfq90e4